AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca, in collaboration with Parexel, is conducting a study titled An Open-label, Randomized, Cross-over, Single Dose Study in Healthy Participants to Assess the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Quinidine. The study aims to evaluate the pharmacokinetics and safety of AZD2389, both alone and with quinidine, in healthy individuals. This research is significant as it could provide insights into the drug’s behavior and safety profile, potentially impacting future treatment options.
The study tests two interventions: AZD2389 alone and AZD2389 combined with quinidine, both administered orally. These interventions are designed to assess how quinidine affects the pharmacokinetics of AZD2389.
The study employs a randomized, cross-over design with no masking, focusing on treatment as its primary purpose. Participants are allocated to one of two sequences, receiving single doses of the treatments in different orders, with a washout period in between.
Key dates for the study include a start date of May 12, 2025, and the last update on July 10, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
This study update could influence AstraZeneca’s stock performance by demonstrating ongoing research and potential new drug applications. Investors may view this as a positive development, especially if the study results in favorable data. The collaboration with Parexel also highlights AstraZeneca’s commitment to advancing its drug pipeline.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.